SMN2 and spinal muscular atrophy, type 1: Initially, the safety and efficacy of a single IV infusion of onasemnogene abeparvovec was examined in the phase 1 START trial (NCT02122952), which involved symptomatic infants <8 months of age with SMA type 1 and who possessed two copies of SMN2.